Coumarin

Coumarin

SCHEMBL1707602

CCCC.O=c1ccc2ccccc2o1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 9/20 0.80
CA9 Q16790 9/20 0.80
CA1 P00915 8/20 0.80
CA7 P43166 7/20 0.80
CA14 Q9ULX7 7/20 0.80
CA6 P23280 6/20 0.80
CA4 P22748 6/20 0.80
CA5B Q9Y2D0 5/20 0.80
CA2 P00918 5/20 0.80
CA5A P35218 5/20 0.80
CA3 P07451 5/20 0.80
MCL1 Q07820 2/20 0.80
TDP1 Q9NUW8 2/20 0.80
LMNA P02545 2/20 0.80
SOST Q9BQB4 1/20 0.80
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 4/20 0.50
GLA P06280 2/20 0.50
CYP1A2 P05177 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL21084335 0.90 CA12 (0.77) CA12CA9CA1CA7CA14
Coumarin SCHEMBL8214245 0.90 CA12 (0.77) CA12CA9CA1CA7CA14
Coumarin SCHEMBL29385611 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL28886137 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL6252 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL3441294 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL621751 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL1038138 0.89 CA12 (1.00) CA12CA9CA1CA7CA14
Coumarin SCHEMBL11101317 0.88 CA12 (0.87) CA12CA9CA1CA7CA14
Coumarin SCHEMBL9643642 0.87 CA12 (0.95) CA12CA9CA1CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680677-A1 BENZOTHIENOPYRROLE CYANINE DYES Beckman Coulter, Inc. (US) 2026-01-21 EP disclosed
US-20250383357-A1 NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES BECKMAN COULTER INC (US) 2025-12-18 US disclosed
EP-4547759-A2 NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES Beckman Coulter, Inc. (US) 2025-05-07 EP disclosed
WO-2025064842-A1 DIHYDROPHENANTHRENE (DHP) BRIDGED DYES FOR USE IN FLOW CYTOMETRY BECKMAN COULTER, INC. (US) 2025-03-27 WO disclosed
US-20240400893-A1 WATER-SOLUBLE TETRAHYDROPYRENE BASED FLUORESCENT POLYMERS BECKMAN COULTER, INC. 2024-12-05 US disclosed
WO-2024196805-A1 BENZOTHIENOPYRROLE CYANINE DYES BECKMAN COULTER, INC. (US) 2024-09-26 WO disclosed
US-20240270971-A1 UV-ABSORBING POLYMERS, COMPOSITIONS AND USES THEREOF BECKMAN COULTER, INC. 2024-08-15 US disclosed
EP-4334395-A1 UV-ABSORBING POLYMERS, COMPOSITIONS AND USES THEREOF Beckman Coulter, Inc. (US) 2024-03-13 EP disclosed
WO-2024044327-A1 DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES BECKMAN COULTER, INC. (US) 2024-02-29 WO disclosed
WO-2024007016-A2 NOVEL FLUORESCENT DYES AND POLYMERS FROM DIHYDROPHENANTHRENE DERIVATIVES BECKMAN COULTER, INC. (US) 2024-01-04 WO disclosed
US-20100297725-A1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. 2010-11-25 US disclosed
US-20100184087-A1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. 2010-07-22 US disclosed
US-7695929-B2 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. (US) 2010-04-13 US disclosed
EP-2167963-A2 POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION Ventana Medical Systems, Inc. (US) 2010-03-31 EP disclosed
EP-2078197-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2009-07-15 EP disclosed
WO-2008153744-A2 POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. (US) 2008-12-18 WO disclosed
US-20080305497-A1 Polymeric carriers for immunohistochemistry and in situ hybridization VENTANA MEDICAL SYSTEMS, INC. 2008-12-11 US disclosed
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. 2008-10-30 US disclosed
WO-2008063378-A9 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MED SYST INC (US) 2008-07-31 WO disclosed
WO-2008063378-A2 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MEDICAL SYSTEMS, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits HRH4, CRBN, NCDN CA12 1373/4885CA9 3488/4885CA1 2248/4885
US-20100297725-A1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use CRBN, GABBR1, SHBG CA12 1700/4885CA9 3668/4885CA1 2839/4885
US-20080305497-A1 Polymeric carriers for immunohistochemistry and in situ hybridization FCGR2A, CD68, CA14 CA12 8/4885CA9 76/4885CA1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.